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Abstract
Objective: In addition to its skeletal effects, vitamin D may also be important for health 
in general. It is uncertain what level of serum 25-hydroxyvitamin D (25(OH)D), marker 
of vitamin D status, is sufficient for these effects. With decreasing serum 25(OH)D levels 
there is an increase in serum PTH. The point at which this occurs has been considered as 
a threshold for vitamin D sufficiency. The thresholds found have varied widely and have 
mainly been based on observational studies. However, to truly establish a threshold for 
vitamin D effects, this has to be based on randomized controlled trials (RCTs).
Methods: The study included 2803 subjects from a general health survey, the Tromsø 
study, and pooled individual person data from five vitamin D intervention studies 
(n = 1544). Serum parathyroid hormone (PTH) and change in PTH after vitamin D 
supplementation were related to serum 25(OH)D levels in steps of 25 nmol/L (<24, 
25–49, 50–74, 75–99, and >99 nmol/L).
Results: In the Tromsø study, in the females there was a gradual decrease in serum PTH 
with increasing serum 25(OH)D with no apparent plateau, whereas in the males the 
decrease in PTH in subjects with serum 25(OH)D >74 nmol/l was marginal. In pooled 
RCTs, there was a significant reduction in serum PTH by vitamin D supplementation 
regardless of baseline serum 25(OH)D level.
Conclusions: The use of the serum PTH–25(OH)D relation from observational studies to 
determine a threshold for vitamin D sufficiency is highly questionable.
Introduction
Vitamin D is essential for intestinal calcium absorption 
and skeletal health. Vitamin D deficiency in children 
may lead to rickets, which can be prevented and/or 
treated by vitamin D supplementation (1). In addition 
to its importance in calcium metabolism and bone 
health, vitamin D may potentially also have a number 
of other health effects. Thus, low serum levels of 
25-hydroxyvitamin D (25(OH)D), which is the currently 
accepted marker of vitamin D status, are associated 
with development of cancer, cardiovascular diseases 
(CVD), diabetes, infections, and immunological diseases 
(2). However, most intervention studies have so far 
not been able to prove positive effects of vitamin D 
supplementation (3, 4), except perhaps in those with 
very low baseline serum 25(OH)D levels (5).
During the last decade, there has been considerable 
debate as to which serum 25(OH)D level is sufficient 
or optimal. The institute of medicine (IOM) has 
recommended that a level of 50 nmol/L is sufficient (6), 
whereas a level of 75 nmol/L has been recommended by 
the Endocrine Society (7). These recommendations are 
partly based on calcium absorption, presence of signs of 
osteomalacia, as well suppression of serum parathyroid 
hormone (PTH) by vitamin D (6, 7, 8).
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Since the serum PTH secretion is mainly regulated 
by the serum calcium level, where a low calcium level 
simulates PTH secretion and a high level inhibits, vitamin 
D may suppress serum PTH levels indirectly by its effect 
on intestinal calcium absorption. Vitamin D may also 
have a direct effect on PTH synthesis and secretion since 
the active form of vitamin D, 1,25-dihydroxyvitamin D 
(1,25(OH)D2), represses the transcription of PTH as well 
as the expression of the calcium-sensing receptor (9). 
Accordingly, a reverse relation between serum PTH and 
25(OH)D has been repeatedly demonstrated, and most 
studies find a sharp increase in serum PTH in the lowest 
serum 25(OH)D ranges (10, 11, 12). The serum 25(OH)D 
level where this PTH increase starts has by many been 
taken as a threshold level for sufficient serum 25(OH)D.
This threshold level has been reported as low as 
30 nmol/L and as high as 100 nmol/L (4), and there are 
even studies where such a threshold or plateau has not 
been found at all (13). Most of these studies have been 
cross-sectional, and to truly define a threshold where a 
higher serum 25(OH)D level will not lead to further PTH 
suppression, this has to be based on randomized controlled 
trials (RCTs) (4). Numerous vitamin D RCTs have included 
serum 25(OH)D and PTH measurements (14), but to our 
knowledge, none has specifically evaluated the effect of 
vitamin D supplementation on serum PTH in subjects 
with high baseline serum 25(OH)D levels.
At the Clinical Research Unit, University Hospital of 
North Norway, we have performed a number of vitamin 
D RCTs and thus have a huge database on PTH responses 
to vitamin D supplementation. Furthermore, the seventh 
survey of the Tromsø study was recently performed, 
where >3000 subjects had both serum 25(OH)D and PTH 
measured. We, therefore, had the opportunity to evaluate 
the PTH–25(OH)D relation both from a cross-sectional 
and interventional point of view.
Materials and methods
Subjects
Individual participant data from the seventh survey of 
the Tromsø study and six intervention studies performed 
in Tromsø, Northern Norway, are used in the present 
analyses. These studies have been described in detail 
before and are summarized in short subsequently.
The Tromsø study is a population-based health 
survey performed for the first time in 1974 in Tromsø, 
Northern Norway at 69° North. The seventh survey was 
performed in 2015–2016. All citizens aged 40 years and 
above and living in the municipality of Tromsø were 
invited and 21,083 (64.7%) attended (15, 16). Serum 
PTH was measured in a subgroup of 3769 subjects who 
also had attended the fourth survey in 1994–1995.
The Obesity study (performed 2005–2007) included 
445 overweight subjects, randomized to vitamin D 4 
0,000 IU per week, 20,000 IU per week, or placebo for 
1 year. All subjects were also given 500 mg calcium daily. 
The primary end point was weight reduction after 1 year. 
The subjects met to visits every third month (17).
The Depression study (performed 2008–2010) 
included 243 healthy subjects randomized to vitamin D 
40,000 IU per week vs placebo for 6 months. The main 
endpoint was reduction in symptoms of depression 
evaluated with a range of depression inventories and 
scales (18). The study was registered at ClinicalTrials.gov 
(NCT00960232).
The Glucose clamp study (performed 2008–2010) 
included 108 healthy subjects randomized to vitamin D 
40,000 IU per week vs placebo for 6 months. The main 
endpoint was change in insulin sensitivity and secretion, 
as evaluated by a hyperglycemic glucose clamp technique 
(19). The study was registered at ClinicalTrial.gov 
(NCT00809744).
The Osteoporosis study (performed 2007–2010) 
included 297 postmenopausal women with bone mass 
density (BMD) T-score ≤−2.0 in either lumbar spine or 
total hip. They were randomized to 6500 IU vitamin D 
per day (20,000 IU twice per week + 800 IU per day) or 800 
IU vitamin D per day (placebo + 800 IU per day) for 1 year 
and met to visits every third month. Both groups were 
given 1000 mg elemental calcium per day. The primary 
endpoint was change in BMD (20).
The CVD risk factor study (performed 2015–2017) 
included 422 healthy subjects randomized to vitamin 
D (100,000 IU loading dose, followed by 20,000 IU per 
week) or placebo for 4 months. The main endpoints were 
change in CVD risk factors (21). The study was registered 
at ClinicalTrials.gov (NCT02750293).
The Prevention of T2DM study (performed 2008–
2015) included 511 subjects with prediabetes who were 
randomized to vitamin D 20,000 IU per week vs placebo 
for 5 years. The subjects met to visits annually. The main 
endpoint was progression to type 2 diabetes (T2DM) 
(22). The study was registered at ClinicalTrials.gov 
(NCT00685594).
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Measurements
Serum 25(OH)D was determined in the Depression, 
Glucose clamp, and Osteoporosis studies at the Hormone 
Laboratory, Haukeland University Hospital, Bergen, using 
an in-house-developed liquid chromatography double mass 
spectrometry (LC/MS-MS) method. All other biochemical 
analyses were performed at the Department of Medical 
Biochemistry, University Hospital of North Norway, 
Tromsø. Both laboratories take part in the external quality 
program DEQAS. Serum 25(OH)D in the Obesity study was 
determined by immunometry (electrochemiluminescence: 
ECLIA) using an automated clinical chemistry analyser 
(Modular E170, Roche Diagnostics) and in the three other 
studies by an in-house-developed LC/MS-MS method. Serum 
PTH in the Tromsø study and the CVD risk factor study was 
analysed with an electrochemiluminescence immunoassay 
(ECLIA) using an automated clinical chemistry analyser 
(Cobas 6000, Roche) and serum calcium by an automated 
analyser (Modular P, Roche Diagnostics) with reagents from 
Boehringer Mannheim. In the five other studies, serum 
PTH was measured using an automated clinical chemistry 
analyzer (Immulite 2000, Siemens Healthcare Diagnostics) 
and serum calcium with an automated analyser (Hitachi 
917) with reagents from Boehringer Mannheim. Reference 
ranges for serum PTH were 1.1–6.8 pmol/L for those 
<51 years and 1.1–7.5 pmol/L for those >50 years and for 
serum calcium 2.20–2.50 mmol/L.
Height and weight were measured wearing light 
clothing, and BMI was calculated as kg/m2.
Statistical analyses
Normal distribution was evaluated for skewness and 
curtosis and by visual inspection of histograms and found 
normal except for serum PTH which was normalized by 
log transformation before use as dependent variable. 
Comparisons between groups were performed with 
Student’s t-test or with a general linear model with 
adjustments as indicated in the text. Linear trends were 
evaluated with linear regression with adjustments as 
indicated in the tables. Only subjects who completed 
the studies and had valid serum 25(OH)D and PTH 
measurements were included. In the Prevention of T2DM, 
two cohorts were analysed, all those who completed 
1 year and those who completed 5 years.
The data are shown as mean ± s.d. All tests were done 
two-sided, and a P-value <0.05 was considered statically 
significant. The P-values are shown without corrections 
for multiple comparisons.
Ethics
All studies were approved by the Regional Committee for 
Medical and Health Research Ethics (REK Nord) and only 
participants with valid written consent were included.
Results
The seventh survey of the Tromsø study
Three thousand seven hundred sixty-nine subjects had 
valid serum 25(OH)D and PTH measurements. Among 
these, 2803 (1682 females and 1121 males) had serum 
calcium in the range 2.20–2.50 mmol/L and serum 
creatinine <100 µmol/L and were included in the 
analyses. When all subjects were analysed together, as 
well as in females and males separately, there was with 
increasing serum 25(OH)D level (in steps of 25 nmol/L) 
a significant increase in age and serum calcium and 
a significant decrease in serum PTH and BMI (Table 1). 
The decrease in serum PTH was attenuated with higher 
serum 25(OH)D levels. However, when comparing those 
in the serum 25(OH)D group of 74–99 nmol/L with 
those in the group with serum 25(OH)D >99 nmol/L and 
adjusting for age and BMI, the serum PTH levels were 
significantly (P < 0.01) lower in the latter group. This 
was also seen when analysing the females separately, 
whereas the difference in serum PTH between these two 
serum 25(OH)D groups was not statistically significant 
for males. However, in males, when comparing the serum 
25(OH)D 50–74 nmol/L group with the serum 25(OH)D 
75–99 nmol/L group, the difference in serum PTH was 
statistically significant (P < 0.05) (Table 1). This apparent 
difference between females and males, as well as the 
increasingly higher PTH levels in the lower serum 25(OH)D 
ranges, are further illustrated in Figs 1 and 2, where 
the serum 25(OH)D levels between 20 and 100 nmol/L 
are divided in steps of 10 nmol/L. In the females, there 
appeared to be a gradual decrease in serum PTH also with 
serum 25(OH)D >50 nmol/L, whereas the corresponding 
decrease in the males was marginal.
Pooled intervention studies
The baseline characteristics of the subjects who completed 
the intervention and had valid serum 25(OH)D and PTH 
measurements are shown for each of the intervention 
studies in Table 2. When the Obesity (n = 332), Depression 
(n = 228), Glucose clamp (n = 93), CVD risk factors 
(n = 411), and Prevention of T2DM (n = 480 (subjects who 
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completed 1 year of the intervention)) studies were pooled 
together and the subjects grouped according to baseline 
serum 25(OH)D level (<25, 25–49, 50–74, 75–99, and 
>99 nmol/L), there was with increasing baseline serum 
25(OH)D, a significant decrease in baseline serum PTH, 
and an increase in serum calcium (Table 3).
In those given vitamin D, the increase in mean serum 
25(OH)D ranged from 70 nmol/L in those with baseline 
values <25 nmoL/L, to 32 nmol/L in those with baseline 
values >99 nmol/L. In the placebo group, there was an 
increase in serum 25(OH)D in those with baseline values 
<50 nmol/L and a decrease in those with higher baseline 
values (Table 3). As compared to those given placebo, 
there was an increase in serum calcium in those given 
vitamin D, which was statistically significant for those 
with baseline serum 25(OH)D 25–49 nmol/L (Table 3). 
In all the baseline serum 25(OH)D groups (<25, 25–49, 
50–74, 75–99, and >99 nmol/L), those given vitamin D 
had a significant reduction in serum PTH compared to 
those given placebo. This reduction was most pronounced 
in those with baseline serum 25(OH)D <25 nmol/L (Table 
3). To examine if this reduction in serum PTH by vitamin 
D supplementation was a result of the increase in serum 
calcium, the previously mentioned analyses were also 
done with adjustment for change in serum calcium. This 
made the difference in delta PTH for those in the serum 
Table 1 Age, BMI, serum PTH, and calcium in relation to serum 25(OH)D levels in 2803 subjects in the seventh survey of the 
Tromsø study.
Serum 25(OH)D (nmol/L)
<25 25–49 50–74 75–99 >99 
All subjects (n) 23 459 1296 788 237
 Age (years) 66.0 ± 13.4 67.5 ± 11.0 69.6 ± 9.9 70.5 ± 8.9 71.4 ± 8.4a
 BMI (kg/m2) 29.4 ± 6.3 28.7 ± 5.1 27.5 ± 4.5 26.6 ± 4.2 25.7 ± 3.9a
 Serum 25(OH)D (nmol/L) 22 ± 3 41 ± 6 63 ± 7 85 ± 7 113 ± 13
 Serum PTH (pmol/L) 6.8 ± 2.7 6.3 ± 2.0 5.5 ± 1.7 5.3 ± 1.6 4.9 ± 1.5a
 Serum calcium (mmol/L) 2.37 ± 0.08 2.35 ± 0.07 2.36 ± 0.07 2.37 ± 0.07 2.38 ± 0.07a
Females (n) 12 226 760 517 167
 Age (years) 66.3 ± 14.5 67.5 ± 11.5 69.4 ± 10.3 70.5 ± 8.7 71.9 ± 8.3a
 BMI (kg/m2) 31.7 ± 7.2 28.9 ± 5.8 27.4 ± 4.8 26.4 ± 4.5 25.6 ± 4.2a
 Serum 25(OH)D (nmol/L) 21 ± 2 41 ± 7 64 ± 7 85 ± 7 113 ± 14
 Serum PTH (pmol/L) 7.4 ± 3.0 6.5 ± 2.2 5.7 ± 1.8 5.3 ± 1.6 4.9 ± 1.5a
 Serum calcium (mmol/L) 2.38 ± 0.07 2.35 ± 0.07 2.36 ± 0.07 2.37 ± 0.07 2.39 ± 0.06a
Males (n) 11 233 536 271 70
 Age (years) 65.6 ± 12.6 67.5 ± 10.6 69.8 ± 9.5 70.5 ± 9.2 70.2 ± 8.5a
 BMI (kg/m2) 26.9 ± 4.0 28.6 ± 4.3 27.7 ± 4.0 26.8 ± 3.6 26.1 ± 3.2a
 Serum 25(OH)D (nmol/L) 22 ± 4 41 ± 6 63 ± 7 85 ± 7 113 ± 10
 Serum PTH (pmol/L) 6.2 ± 2.4 6.1 ± 1.9 5.3 ± 1.6 5.1 ± 1.7 5.1 ± 1.5a
 Serum calcium (mmol/L) 2.37 ± 0.08 2.35 ± 0.07 2.36 ± 0.07 2.36 ± 0.07 2.37 ± 0.07a
aP < 0.01 (linear trend, adjusted for age and BMI).
Figure 1
Mean serum PTH in relation to serum 25(OH)D in 1695 females in the 
seventh survey of the Tromsø study.
Figure 2
Mean serum PTH in relation to serum 25(OH)D in 1124 males in the 
seventh survey of the Tromsø study.
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25(OH)D group 75–99 nmol/L non-significant (P = 0.058), 
whereas the other significance levels did not change.
Effects of time and vitamin D dose on the 
PTH suppression
In the Prevention of T2DM study, 227 subjects completed 
the 5-year intervention with valid serum 25(OH)D and 
PTH measurements. In the vitamin D group, there was 
an increase in mean serum 25(OH)D of 50–60 nmol/L, 
whereas the serum 25(OH)D levels in the placebo group 
remained stable at baseline levels. There was a decrease 
in serum PTH in the vitamin D group compared to the 
placebo group, which was statistically significant after 1, 
3, 4, and 5 years. After the decrease in serum PTH during 
the first year, the serum PTH levels in the vitamin D group 
remained stable till the end of the study (Table 4).
In the Obesity study, 332 subjects completed the 
1-year intervention with valid serum 25(OH)D and PTH 
measurements. In the group given vitamin D 40,000 IU 
per week, mean serum 25(OH)D increased ~60 nmol/L 
and in the group given 20,000 IU per week the increase 
in serum 25(OH)D was ~40 nmol/L and remained stable 
at baseline levels in the placebo group. In both vitamin 
D groups, the maximal decrease in serum PTH occurred 
already after 3 months. The decrease in serum PTH was, 
throughout the intervention, significantly larger in the 
40,000 IU per week group as compared to the placebo 
group, but not as compared to the group given 20,000 IU 
per week (Table 5).
In the Osteoporosis study, 273 women completed 
the 1-year intervention with valid measurements. In 
the group given vitamin D 45,600 IU per week, serum 
25(OH)D increased 100–115 nmol/L, whereas the increase 
Table 2 Baseline characteristics of the six intervention studies in those who completed the study and had valid serum 25(OH)D 
and PTH measurements.
Study Females/males (n/n) Age (years) BMI (kg/m2)
Serum 25(OH)D  
(nmol/L)




Obesity 203/129 49.2 ± 11.2 34.6 ± 3.9 54 ± 27 5.4 ± 1.7 2.31 ± 0.10
Depression 128/100 51.8 ± 10.2 27.7 ± 4.1 48 ± 16 5.0 ± 1.9 2.28 ± 0.08
Glucose clamp 45/48 52.2 ± 9.2 26.8 ± 3.0 41 ± 13 5.2 ± 1.5 2.31 ± 0.09
Osteoporosis 273/0 63.1 ± 7.1 24.7 ± 3.4 71 ± 23 5.1 ± 1.7 2.36 ± 0.08
CVD risk factors 192/219 52.0 ± 8.7 27.9 ± 4.9 34 ± 12 6.7 ± 2.0 2.27 ± 0.07
Prevention of T2DMa 183/297 62.0 ± 8.6 29.9 ± 4.3 61 ± 22 5.7 ± 2.2 2.31 ± 0.08
Prevention of T2DMb 82/145 62.2 ± 8.1 29.3 ± 3.8 63 ± 22 5.6 ± 2.3 2.31 ± 0.08
All studies 1024/793 55.8 ± 10.8 29.1 ± 5.2 52 ± 22 5.7 ± 2.0 2.31 ± 0.09
aSubjects who completed 1 year of the intervention; bSubjects who completed 5 years of the intervention.
Table 3 Baseline and change (delta values) in serum 25(OH)D, PTH, and calcium in relation to intervention and baseline serum 
25(OH)D level, the Obesity, Depression, Glucose clamp, CVD risk factors, and Prevention of T2DM studies pooled together.
Group
Baseline serum 25(OH)D (nmol/L)
<25 25–49 50–74 75–99 >99
Number of subjectsf (females/males) Vitamin D 24/43 196/214 136/133 45/33 5/7
Placebo 28/34 162/168 115/130 33/24 7/7
Baseline serum 25(OH)D (nmol/L) Vitamin D 20 ± 4 38 ± 7 60 ± 7 83 ± 7 122 ± 24
Placebo 20 ± 4 38 ± 7 60 ± 7 84 ± 7 113 ± 15
Delta serum 25(OH)D (nmol/L) Vitamin D 67 ± 26c 67 ± 33c 53 ± 29c 48 ± 29c 32 ± 32ce
Placebo 7 ± 9 3 ± 13 −1 ± 17 −7 ± 17 −16 ± 17e
Baseline serum PTH (pmol/L) Vitamin D 7.1 ± 2.5 5.9 ± 2.1 5.5 ± 1.9 4.8 ± 1.6 5.5 ± 2.1e
Placebo 7.2 ± 2.3 6.2 ± 2.2 5.3 ± 1.8 4.9 ± 1.7 4.2 ± 1.0e
Delta serum PTH (pmol/L) Vitamin D −1.4 ± 1.8c −0.6 ± 1.4c −0.7 ± 1.5c −0.3 ± 1.5a −0.8 ± 1.6ad
Placebo 0.0 ± 1.5 0.3 ± 1.7 0.3 ± 1.6 0.2 ± 0.9 0.5 ± 1.0
Baseline serum calcium (mmol/L) Vitamin D 2.28 ± 0.07 2.29 ± 0.08 2.30 ± 0.10 2.31 ± 0.08 2.34 ± 0.07d
Placebo 2.27 ± 0.07 2.28 ± 0.08 2.31 ± 0.09 2.31 ± 0.08 2.30 ± 0.06e
Delta serum calcium (mmol/L) Vitamin D 0.01 ± 0.07 0.00 ± 0.09b −0.02 ± 0.09 −0.02 ± 0.10 −0.07 ± 0.05ae
Placebo 0.00 ± 0.07 −0.02 ± 0.09 −0.03 ± 0.08 −0.04 ± 0.09 −0.02 ± 0.07
Delta values are end of study values minus baseline (for the Prevention of T2DM study 1-year values minus baseline).
aP < 0.05; bP < 0.01; cP < 0.001 (vs placebo group, Student’s t-test); dP < 0.01; eP < 0.001 (linear trend); fSubjects from the Obesity, Depression, Glucose 
clamp, CVD risk factors, and Prevention of T2DM pooled together. Only subjects who completed the intervention with valid serum 25(OH)D and PTH 
measurements are included.
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in the group given 5600 IU per week was ~ 20 nmol/L. 
At all 3-month intervals, the decrease in serum PTH was 
significantly higher in those given 45,600 IU per week 
and, as in the Obesity study, the lowest PTH levels were 
seen already after 3 months (Table 6).
Discussion
In the cross-sectional part of the present study, we have 
confirmed the well-known inverse relationship between 
serum 25(OH)D and PTH, but could not find a 25(OH)D 
level where the serum PTH stabilized or reached a plateau. 
In the intervention studies, the decrease in serum PTH 
by vitamin D supplementation was dose dependent and 
occurred within 3 months with no further suppression 
thereafter. And most importantly, the serum PTH level 
was significantly supressed by vitamin D supplementation 
even in subjects with serum 25(OH)D levels >100 nmol/L.
There are numerous cross-sectional reports on 
thresholds for serum 25(OH)D suppression of serum 
PTH (10, 11, 12, 23, 24, 25). This has been estimated 
by advanced statistical methods (10, 12) as well as 
with simple visual curve inspection (12). The cohorts 
included have differed widely as have the results. As 
examples can be mentioned, in the large study by Saliba 
et  al., including 19,172 subjects from an Israeli clinical 
laboratory database, a serum 25(OH)D threshold of 79 
nmol/L was found. However, after excluding subjects 
with hypercalcemia and reduced kidney function, the 
threshold was reduced to 46 nmol/L (11). In a study by 
Sohl et al., including 1164 elderly subjects, the threshold 
for women was 68 nmol/L, whereas in men the threshold 
was 45 nmol/L. In the same study, the 25(OH)D threshold 
was also affected by BMI, being 47 nmol/L in those with 
BMI <25 kg/m2 and 62 nmol/L in those with higher 
BMI (12). Among 1258 Caucasians, Wright et  al. found 
a threshold of approximately 75 nmol/L, whereas in 423 
African Americans the threshold was approximately 50 
nmol/L (24). In a study by Durazo-Arvizu et al., including 
387 subjects from an osteoporosis treatment/prevention 
study and using a three-phase model, two thresholds (or 
significant change in the serum PTH–25(OH)D curve) of 
30 and 70 nmol/L could be identified (10). And finally, in 
500 adults of African ancestry, there was an almost linear 
Table 4 Serum 25(OH)D, PTH, and delta PTH in 116 subjects given vitamin D and 111 placebo and who completed the 5-year 
intervention in the prevention of T2DM study.
Serum 25(OH)D (nmol/L) Serum PTH (pmol/L) Delta serum PTH (pmol/L)a
Vitamin D Placebo Vitamin D Placebo Vitamin D Placebo
Baseline 63 ± 23 63 ± 21 5.7 ± 2.1 5.5 ± 2.4
1 year 110 ± 30c 65 ± 22 5.2 ± 1.6 5.7 ± 1.9 −0.6 ± 1.5b 0.2 ± 1.7
2 years 114 ± 24c 64 ± 19 5.5 ± 2.0 5.7 ± 1.7 −0.2 ± 1.5 0.2 ± 1.8
3 years 118 ± 26c 66 ± 20 5.4 ± 1.9 6.0 ± 2.3 −0.3 ± 1.6c 0.5 ± 1.5
4 years 120 ± 26c 65 ± 19 5.3 ± 2.1 5.7 ± 1.9 −0.4 ± 1.6b 0.3 ± 2.0
5 years 122 ± 25c 67 ± 19 5.2 ± 1.7 5.7 ± 2.3 −0.5 ± 1.4c 0.2 ± 1.4
aAnnual serum PTH value minus baseline PTH; bP < 0.01; cP < 0.001 (vs placebo group, Student’s t-test).
Table 5 Serum 25(OH)D, PTH, and delta PTH in the 332 subjects who completed the 1-year intervention in the obesity study.
Baseline 3 months 6 months 9 months 12 months
Serum 25(OH)D (nmol/L)
 Vitamin D 40,000 IU per week (n = 114) 56 ± 16 108 ± 22cd 117 ± 23cd 121 ± 28cd 116 ± 27cd
 Vitamin D 20,000 IU per week (n = 106) 53 ± 19 88 ± 20c 93 ± 21c 95 ± 21c 91 ± 22c
 Placebo (n = 112) 53 ± 16 56 ± 17 59 ± 16 56 ± 15 51 ± 14
Serum PTH (pmol/L)
 Vitamin D 40,000 IU per week (n = 114) 5.1 ± 1.6 3.4 ± 1.2 3.5 ± 1.3 3.6 ± 1.4 4.2 ± 1.5
 Vitamin D 20,000 IU per week (n = 106) 5.5 ± 1.8 4.0 ± 1.7 4.1 ± 1.6 4.2 ± 1.6 4.7 ± 1.7
 Placebo (n = 112) 5.6 ± 1.6 4.4 ± 1.8 4.5 ± 1.8 4.6 ± 1.6 5.4 ± 1.9
Delta serum PTH (pmol/L)
 Vitamin D 40,000 IU per week (n = 114) −1.8 ± 1.5a −1.7 ± 1.5b −1.6 ± 1.5a −0.9 ± 1.5b
 Vitamin D 20,000 IU per week (n = 106) −1.5 ± 1.4 −1.4 ± 1.6 −1.3 ± 1.4 −0.8 ± 1.4b
 Placebo (n = 112) −1.2 ± 1.6 −1.1 ± 1.4 −1.0 ± 1.7 −0.3 ± 1.6
Delta values are the specific month value minus baseline. Only subjects who completed the intervention with valid serum 25(OH)D and PTH 
measurements are included.
aP < 0.05; bP < 0.01; cP < 0.001 (vs placebo, Student’s t-test); dP < 0.001 (vs the vitamin D 20,000 IU per week group, Student’s t-test).
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relation between serum PTH and 25(OH)D in the serum 
25(OH)D 25–150 nmol/L range (23).
Our observational study adds to this multitude of 
thresholds or lack of such. In the males, the decrease 
in serum PTH in those with serum 25(OH)D >50–75 
nmol/L was marginal, whereas in the females no plateau 
was reached, at least not below 100 nmol/L. Even if the 
ideal observational study on the serum PTH–25(OH)D 
relation was performed in a population-based cohort 
where adjustments could be made for relevant factors like 
calcium and magnesium intake and where the number 
of subjects were large enough to do subgroup analyses in 
males and females, in young and old, in low-, normal-, 
and overweight subjects, one would not be able to reliably 
identify a threshold (or lack of such) where no additional, 
meaningful PTH suppression by vitamin D would occur. 
This is simply because one cannot imply causality from 
observational data, and the 25(OH)D threshold, similar to 
health effects of vitamin D, has to be tested in RCTs (4, 26).
The effect of vitamin D on serum PTH in RCTs was 
systematically reviewed by Björkman et  al., where 41 
clinical trials were included, and the results suggested that 
serum PTH would decrease quite linearly during vitamin D 
supplementation at any given serum 25(OH)D level (14). 
However, in the majority of the studies, the mean baseline 
serum 25(OH)D level was <50 nmol/L and no study had 
mean baseline serum 25(OH)D >85 nmol/L. Individual 
person data (IPD) were not used in the analyses, and 
accordingly, the PTH–25(OH)D relation in subjects with 
serum 25(OH)D >85 nmol/L not investigated.
In our intervention studies, we found that the 
serum PTH suppression by vitamin D appeared to reach 
its full effect after 3 months as demonstrated in the 
Obesity and Osteoporosis studies and that even 5 years 
with continuously high serum 25(OH)D levels had 
no additional effect in the Prevention of T2DM study. 
Furthermore, we confirmed the importance of the vitamin 
D dose given (27), as the suppression of serum PTH in the 
Osteoporosis study was considerably higher with vitamin 
D 45,600 IU per week vs the 5600 IU per week. On the 
other hand, there was no significant difference in PTH 
suppression between 40,000 IU per week vs 20,000 IU per 
week in the Obesity study. We, therefore, found it relevant 
to pool the baseline and end of study (or 1 year) IPD 
from the Obesity, Depression, Glucose clamp, CVD risk 
factors, and the Prevention of T2DM studies, even though 
different vitamin D doses and intervention times were 
used. With this approach the cohort became sufficiently 
large to allow meaningful analyses of PTH suppression in 
a broad range of baseline serum 25(OH)D levels.
As expected, the suppression was most pronounced 
in those with low baseline serum 25(OH)D, who also had 
the highest baseline PTH and, also as expected (28), the 
highest increase in serum 25(OH)D after supplementation. 
However, there was a substantial and statistically 
significant decrease in serum PTH even in those with 
baseline serum 25(OH)D >100 nmol/L. This reduction in 
serum PTH was statistically significant also after adjusting 
for the concomitant changes in serum calcium, indicating 
a direct effect by vitamin D on the PTH synthesis/
secretion. Accordingly, it is very difficult to justify using 
cross-sectional data to identify a 25(OH)D threshold at a 
serum 25(OH)D level of ~50 nmol/L. In addition, serum 
PTH suppression is for vitamin D supplementation only a 
surrogate marker for health effects and should not be used 
to define vitamin D sufficiency.
Even though there are strong indications for extra-
skeletal effects of vitamin D, like the wide tissue distributing 
of the vitamin D receptor (VDR) and the enzymes 
necessary for activation of vitamin D (1), together with all 
Table 6 Serum 25(OH)D, PTH, and delta PTH in the 273 postmenopausal women who completed the 1-year intervention in the 
Osteoporosis study.
Baseline 3 months 6 months 9 months 12 months
Serum 25(OH)D (nmol/L)
 Vitamin D 45,600 IU per week (n = 135) 71 ± 23 168 ± 27b 177 ± 32b 187 ± 32b 186 ± 34b 
 Vitamin D 5600 IU per week (n = 140) 71 ± 22 91 ± 19 93 ± 24 90 ± 18 89 ± 17
Serum PTH (pmol/L)
 Vitamin D 45,600 IU per week (n = 135) 5.0 ± 1.6 3.5 ± 1.3 3.7 ± 1.2 3.7 ± 1.2 3.9 ± 1.1
 Vitamin D 5600 IU per week (n = 140) 5.0 ± 1.6 3.9 ± 1.3 4.2 ± 1.5 4.2 ± 1.5 4.5 ± 1.5
Delta serum PTH (pmol/L)
 Vitamin D 45,600 IU per week (n = 135) −1.5 ± 1.2a −1.4 ± 1.4b −1.3 ± 1.5b −1.2 ± 1.4b
 Vitamin D 5600 IU per week (n = 140) −1.1 ± 1.4 −0.8 ± 1.5 −0.8 ± 1.4 −0.6 ± 1.5
Delta values are the specific month value minus baseline. Only subjects who completed the intervention with valid serum 25(OH)D and PTH 
measurements are included. All subjects were given 1000 mg calcium daily.
aP < 0.05; bP < 0.01 (vs vitamin D 5600 IU per week, Student’s t-test).
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-20-0067
https://ec.bioscientifica.com © 2020 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 01/05/2021 08:43:06AM
via free access
R Jorde and G Grimnes Serum 25(OH)D threshold 403
PB–XX
9:5
the favourable observational studies, firm evidence from 
RCTs is lacking (3, 29). Estimates of vitamin D thresholds 
based on extra-skeletal effects of vitamin D are therefore at 
present not relevant. For fractures, on the other hand, there 
appears to be fairly good evidence for a protective effect of 
combined use of calcium and vitamin D, but this has so far 
not been definitely related to a serum 25(OH)D level (29).
Serum PTH is the parameter most consistently 
associated with serum 25(OH)D both in cross-sectional 
and interventional studies. In spite of this, a wide range of 
25(OH)D thresholds have been reported, which probably 
also will be the case for skeletal effects of vitamin D. It is also 
likely that such a serum 25(OH)D threshold will be affected 
by calcium intake, similar to what is seen for the risk of 
rickets in children where a high calcium intake is protective 
(29). A high calcium intake increases the half-life of 
25(OH)D and may thus be good for the vitamin D economy 
(30). This may influence the 25(OH)D–PTH relation, as 
demonstrated by Patel et al. who found lower serum PTH 
values for given 25(OH)D concentrations in subjects with 
high calcium intake (31). A low dietary magnesium intake 
may also alter the 25(OH)D–PTH relationship, at least in 
overweight or obese subjects (32). Differences in calcium 
and magnesium intakes may therefore partly explain the 
wide range in 25(OH)D thresholds reported. Additionally, 
other factors like BMI, age, ethnicity, and gender may 
influence the threshold, which may even differ between 
the endpoints used for threshold identification (12, 24). 
Finding a clinically relevant and trustworthy threshold for 
vitamin D sufficiency may therefore prove difficult.
Our study has several weaknesses. Although we had 
large cohorts both in the observational and interventional 
parts of the study, relatively few subjects had very high 
baseline serum 25(OH)D levels. Therefore, we cannot 
draw conclusions about the serum PTH–25(OH)D 
relation in subjects with serum 25(OH)D > ~125 nmol/L. 
Although we feel we have justified pooling the five 
intervention studies together, they were still different 
studies with different inclusion criteria and interventions. 
Furthermore, different laboratories and assays were used 
for the 25(OH)D and PTH measurements, without any 
formal examination of consistency between the analytic 
methods. This could be of particular importance for 
PTH where there is no standardization program, and we 
cannot rule out that this may have affected the results. 
On the other hand, our study also has several strengths. 
In the observational part, we only included subjects with 
normal serum calcium and creatinine levels, and in the 
interventional part, we examined the PTH–25(OH)D 
relation over a broad range of serum 25(OH)D levels.
In conclusion, we have found that serum PTH is 
suppressed by vitamin D supplementation even if the 
baseline serum 25(OH)D is >100 nmol/L. This argues 
against using serum PTH suppression to define vitamin 
D sufficiency.
Declaration of interest
The authors declare that there is no conflict of interest that could be 
perceived as prejudicing the impartiality of the research reported.
Funding
The Tromsø study was supported by grants from the North Norway 
Regional Health Authorities (grant number SFP1277-16) and UiT The Arctic 
University of Norway; the Obesity and Depression studies supported by 
grants from The Northern Norway Regional Health Authority; the Glucose 
clamp and Osteoporosis studies supported by the Norwegian Council of 
Cardiovascular Disease; the CVD risk factor study supported by grants 
from the North Norway Regional Health Authorities (grant number 
SFP1277-16) and UiT The Arctic University of Norway; and the Prevention 
of T2DM supported by grants from the Novo Nordisk Foundation (Grant 
R195-A16126), the North Norway Regional Health Authorities (Grant 6856/
SFP1029-12), UiT The Arctic University of Norway, the Norwegian Diabetes 
Association, and the Research Council of Norway (Grant 184766).
Acknowledgements
The superb assistance from the staff at the Clinical Research Unit at the 
University Hospital of North Norway is gratefully acknowledged.
References
 1 DeLuca HF. Overview of general physiologic features and functions 
of vitamin D. American Journal of Clinical Nutrition 2004 80 
1689S–1696S. (https://doi.org/10.1093/ajcn/80.6.1689S)
 2 Holick MF. Vitamin D deficiency. New England Journal Medicine 2007 
357 266–281. (https://doi.org/10.1056/NEJMra070553)
 3 Theodoratou E, Tzoulaki I, Zgaga L & Ioannidis JP. Vitamin D and 
multiple health outcomes: umbrella review of systematic reviews and 
meta-analyses of observational studies and randomised trials. BMJ 
2014 348 g2035. (https://doi.org/10.1136/bmj.g2035)
 4 Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C, 
Vanderschueren D & Lips P. Optimal vitamin D status: a critical 
analysis on the basis of evidence-based medicine. Journal of Clinical 
Endocrinology and Metabolism 2013 98 E1283–E1304. (https://doi.
org/10.1210/jc.2013-1195)
 5 Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, 
Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Grinde AA, 
et al. Vitamin D supplementation to prevent acute respiratory 
tract infections: systematic review and meta-analysis of individual 
participant data. BMJ 2017 356 i6583. (https://doi.org/10.1136/bmj.
i6583)
 6 Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin 
D. Washington, DC, USA: The National Academies Press, 2011.
 7 Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, 
Heaney RP, Murad MH, Weaver CM & Endocrine Society. Evaluation, 
treatment, and prevention of vitamin D deficiency: an Endocrine 
Society clinical practice guideline. Journal of Clinical Endocrinology and 
Metabolism 2011 96 1911–1930. (https://doi.org/10.1210/jc.2011-
0385)
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-20-0067
https://ec.bioscientifica.com © 2020 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 01/05/2021 08:43:06AM
via free access
R Jorde and G Grimnes Serum 25(OH)D threshold 4049:5
 8 Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, 
Proksch N, Pastor F, Netter C, Streichert T, et al. Bone mineralization 
defects and vitamin D deficiency: histomorphometric analysis of 
iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 
675 patients. Journal of Bone and Mineral Research 2010 25 305–312. 
(https://doi.org/10.1359/jbmr.090728)
 9 Kumar R & Thompson JR. The regulation of parathyroid hormone 
secretion and synthesis. Journal of American Society of Nephrology 2011 
22 216–224. (https://doi.org/10.1681/ASN.2010020186)
 10 Durazo-Arvizu RA, Dawson-Hughes B, Sempos CT, Yetley EA, 
Looker AC, Cao G, Harris SS, Burt VL, Carriquiry AL & Picciano MF. 
Three-phase model harmonizes estimates of the maximal suppression 
of parathyroid hormone by 25-hydroxyvitamin D in persons 65 years 
of age and older. Journal of Nutrition 2010 140 595–599. (https://doi.
org/10.3945/jn.109.116681)
 11 Saliba W, Barnett O, Rennert HS, Lavi I & Rennert G. The 
relationship between serum 25(OH)D and parathyroid hormone 
levels. American Journal of Medicine 2011 124 1165–1170. (https://doi.
org/10.1016/j.amjmed.2011.07.009)
 12 Sohl E, de Jongh RT, Heymans MW, van Schoor NM & Lips P. 
Thresholds for serum 25(OH)D concentrations with respect to 
different outcomes. Journal of Clinical Endocrinology and Metabolism 
2015 100 2480–2488. (https://doi.org/10.1210/jc.2015-1353)
 13 Asghari G, Yuzbashian E, Wagner CL, Mahdavi M, Shamsi R, 
Hosseinpanah F & Mirmiran P. The relation between circulating 
levels of vitamin D and parathyroid hormone in children and 
adolescents with overweight or obesity: quest for a threshold. 
PLoS One 2019 14 e0225717. (https://doi.org/10.1371/journal.
pone.0225717)
 14 Björkman M, Sorva A & Tilvis R. Responses of parathyroid hormone 
to vitamin D supplementation: a systematic review of clinical trials. 
Archives of Gerontology and Geriatrics 2009 48 160–166. (https://doi.
org/10.1016/j.archger.2007.12.005)
 15 Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T & Njølstad I. 
Cohort profile: the Tromso Study. International Journal of Epidemiology 
2012 41 961–967. (https://doi.org/10.1093/ije/dyr049)
 16 Jorde R & Grimnes G. Lost relation between blood pressure and 
serum 25-hydroxyvitamin D. Blood Pressure 2019 28 64–73. (https://
doi.org/10.1080/08037051.2018.1547628)
 17 Sneve M, Figenschau Y & Jorde R. Supplementation with 
cholecalciferol does not result in weight reduction in overweight and 
obese subjects. European Journal of Endocrinology 2008 159 675–684. 
(https://doi.org/10.1530/EJE-08-0339)
 18 Kjærgaard M, Waterloo K, Wang CE, Almås B, Figenschau Y, 
Hutchinson MS, Svartberg J & Jorde R. Effect of vitamin D 
supplement on depression scores in people with low levels of serum 
25-hydroxyvitamin D: nested case-control study and randomised 
clinical trial. British Journal of Psychiatry 2012 201 360–368. (https://
doi.org/10.1192/bjp.bp.111.104349)
 19 Grimnes G, Figenschau Y, Almås B & Jorde R. Vitamin D, insulin 
secretion, sensitivity, and lipids: results from a case-control study and 
a randomized controlled trial using hyperglycemic clamp technique. 
Diabetes 2011 60 2748–2757. (https://doi.org/10.2337/db11-0650)
 20 Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Almås B & 
Jorde R. The effect of high-dose vitamin D on bone mineral density 
and bone turnover markers in postmenopausal women with low 
bone mass – a randomized controlled 1-year trial. Osteoporosis 
International 2012 23 201–211. (https://doi.org/10.1007/s00198-011-
1752-5)
 21 Kubiak J, Thorsby PM, Kamycheva E & Jorde R. Vitamin D 
supplementation does not improve CVD risk factors in vitamin 
D-insufficient subjects. Endocrine Connections 2018 7 840–849. 
(https://doi.org/10.1530/EC-18-0144)
 22 Jorde R, Sollid ST, Svartberg J, Schirmer H, Joakimsen RM, Njølstad I, 
Fuskevåg OM, Figenschau Y & Hutchinson MY. Vitamin D 20,000 IU 
per week for five years does not prevent progression from prediabetes 
to diabetes. Journal of Clinical Endocrinology and Metabolism 2016 101 
1647–1655. (https://doi.org/10.1210/jc.2015-4013)
 23 Kramer H, Camacho P, Aloia J, Luke A, Bovet P, Rhule JP, Forrester T, 
Lambert V, Harders R, Dugas L, et al. Association between 
25-hydroxyvitamin D and intact parathyroid hormone levels across 
latitude among adults of African ancestry. Endocrine Practice 2016 22 
911–919. (https://doi.org/10.4158/EP151079.OR)
 24 Wright NC, Chen L, Niu J, Neogi T, Javiad K, Nevitt MA, Lewis CE 
& Curtis JR. Defining physiologically ‘normal’ vitamin D in African 
Americans. Osteoporosis International 2012 23 2283–2291. (https://
doi.org/10.1007/s00198-011-1877-6)
 25 Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, 
Petruschke RA, Chen E & de Papp AE. Prevalence of Vitamin D 
inadequacy among postmenopausal North American women receiving 
osteoporosis therapy. Journal of Clinical Endocrinology and Metabolism 
2005 90 3215–3224. (https://doi.org/10.1210/jc.2004-2364)
 26 Jorde R & Grimnes G. Vitamin D and health: the need for more 
randomized controlled trials. Journal of Steroid Biochemistry and 
Molecular Biology 2015 148 269–274. (https://doi.org/10.1016/j.
jsbmb.2015.01.021)
 27 Smith LM & Gallagher JC. Effect of vitamin D supplementation 
on total and free 25 hydroxyvitamin D and parathyroid hormone. 
An analysis of two randomized controlled trials. Journal of Internal 
Medicine 2019 286 651–659. (https://doi.org/10.1111/joim.12950)
 28 Didriksen A, Grimnes G, Hutchinson MS, Kjærgaard M, Svartberg J, 
Joakimsen RM & Jorde R. The serum 25-hydroxyvitamin D response 
to vitamin D supplementation is related to genetic factors, BMI, and 
baseline levels. European Journal of Endocrinology 2013 169 559–567. 
(https://doi.org/10.1530/EJE-13-0233)
 29 Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-
Hughes B, Lips P, Munns CF, Lazaretti-Castro M Giustina A, et al. 
Skeletal and extraskeletal actions of vitamin D: current evidence 
and outstanding questions. Endocrine Reviews 2019 40 1109–1151. 
(https://doi.org/10.1210/er.2018-00126)
 30 Lips P. Interaction between vitamin D and calcium. Scandinavian 
Journal of Clinical and Laboratory Investigation 2012 72 (Supplement 
243) 60–64. (https://doi.org/10.3109/00365513.2012.681960)
 31 Patel P, Mughal MZ, Patel P, Yagnik B, Kajale N, Mandlik R, 
Khadilkar V, Chiplonkar SA, Phanse S, Patwardhan V, et al. 
Dietary calcium intake influences the relationship between serum 
25-hydroxyvitamin D3 (25OHD) concentration and parathyroid 
hormone (PTH) concentration. Archives of Disease in Childhood 2016 
101 316–319. (https://doi.org/10.1136/archdischild-2015-308985)
 32 Cheung MM, DeLuccia R, Ramadoss RK, Aljahdali A, Volpe SL, 
Shewokis PA & Sukumar D. Low dietary magnesium intake alters 
vitamin D-parathyroid hormone relationship in adults who are 
overweight or obese. Nutrition Research 2019 69 82–93. (https://doi.
org/10.1016/j.nutres.2019.08.003)
Received in final form 8 April 2020
Accepted 21 April 2020
Accepted Manuscript published online 21 April 2020
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-20-0067
https://ec.bioscientifica.com © 2020 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 01/05/2021 08:43:06AM
via free access
